Gennex Laboratories board meets on May 30 for Q4FY26 results

1 min read     Updated on 20 May 2026, 04:55 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Gennex Laboratories Limited will hold a board meeting on May 30, 2026, to approve audited financial results for the quarter and year ended March 31, 2026. The meeting will be held in Hyderabad, and the notice was published in major newspapers on May 20, 2026.

powered bylight_fuzz_icon
40821911

*this image is generated using AI for illustrative purposes only.

Gennex Laboratories Limited has announced that its board of directors will meet on Saturday, May 30, 2026. The primary agenda of the meeting is to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with the report of the statutory auditors.

The meeting is scheduled to take place at the corporate office of the company located at Akash Ganga, 04th Floor, Plot No.144, Srinagar Colony, Hyderabad – 500 073, Telangana State, India. The proceedings will be conducted in compliance with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company has intimated the stock exchanges regarding the meeting. The notice was published in both Business Standard and Saksham (Local-Telugu) newspapers on May 20, 2026. The official notice is also available on the company's website and the BSE Limited website for shareholder reference.

Meeting Details Information
Date May 30, 2026
Day Saturday
Time Not specified
Location Hyderabad, Telangana
Agenda Audited Financial Results for Q4 and FY26

The adoption of the audited financial results for the full fiscal year and the fourth quarter is a key regulatory requirement. Shareholders and investors can access the detailed results once they are approved and officially filed following the board meeting.

Historical Stock Returns for Gennex Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%+11.05%+6.31%-25.05%-16.48%+68.98%

How did Gennex Laboratories' revenue and profitability trends for FY26 compare to the previous fiscal year, and what drove any significant changes?

Will Gennex Laboratories announce any dividend declaration or capital allocation plans following the approval of FY26 audited results?

What strategic expansions or pipeline developments is Gennex Laboratories planning for FY27 that could impact its financial outlook?

Gennex Labs Approves Director Regularization at EGM

4 min read     Updated on 13 May 2026, 07:19 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Gennex Laboratories Limited conducted an electronic Extraordinary General Meeting on May 12, 2026, to approve the regularization of Ms. Khushbu Kachhawa as a Non-Executive Independent Woman Director. The resolution was passed with 99.9997% of the total votes polled, with 31,176,049 shares voting in favor and 87 against.

powered bylight_fuzz_icon
40129824

*this image is generated using AI for illustrative purposes only.

Gennex Laboratories Limited held an electronic Extraordinary General Meeting (eEGM) on May 12, 2026, through Video Conferencing (VC) and Other Audio Visual Means (OAVM). The meeting was convened to transact special business regarding the regularization of an Additional Director. The proceedings commenced at 12:30 p.m. and concluded at 01:18 p.m., complying with relevant Ministry of Corporate Affairs and SEBI circulars. A total of 47 members attended the meeting via VC, satisfying the requisite quorum.

Voting Results

Shareholders approved the sole resolution on the agenda with an overwhelming majority. The resolution sought the regularization of Ms. Khushbu Kachhawa (DIN: 10872432) as a Non-Executive Independent Woman Director. This appointment was necessary to comply with SEBI (LODR) Regulations, which require the regularization of an Additional Director within three months of their appointment.

The voting process included remote e-voting, which was open from May 8 to May 11, 2026, and e-voting during the meeting. Ms. Sweety Kapoor, Practising Company Secretary, served as the Scrutinizer for the process.

Resolution Votes For Votes Against % For
Regularization of Director Ms. Khushbu Kachhawa 31,176,049 87 99.9997

Meeting Participation

A total of 91 members participated in the voting process through remote e-voting and during the EGM. The total number of votes cast was 31,176,136. Promoter and Promoter Group held 57,405,624 shares, while Public Non-Institutions held 185,542,050 shares as on the record date of May 1, 2026.

The Chairman, Mr. Arihant Baid, presided over the meeting, which was also attended by directors including Dr. Avasarala Ranga Rao Pantulu and Mr. Sandeep Kumar Daga. The Consolidated Scrutinizer's Report confirming these results has been submitted to the stock exchanges and uploaded on the Company's website.

Historical Stock Returns for Gennex Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%+11.05%+6.31%-25.05%-16.48%+68.98%

How might Ms. Khushbu Kachhawa's appointment as Independent Woman Director influence Gennex Laboratories' corporate governance strategy and board-level decision-making going forward?

Given the Chairman's discussion of challenges and opportunities in India's pharma sector, what specific growth initiatives or expansion plans is Gennex Laboratories likely to pursue in the near term?

With only 12.83% of outstanding shares participating in the vote, what steps might Gennex Laboratories take to improve shareholder engagement and retail investor participation in future general meetings?

More News on Gennex Laboratories

1 Year Returns:-16.48%